Archives header

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Regardless of type 2 diabetes status, pancreatic cancer risk was reduced with metabolic-bariatric surgery for patients who were obese.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.

Detailed results from the phase 3 TALAPRO-2 trial will be submitted for presentation at a future medical meeting and shared with global health authorities.